



EPASG

European Society of Clinical Microbiology and Infectious Diseases

ESCMID PK/PD
OF ANTI-INFECTIVES
STUDY GROUP




International
Society of
Anti-Infective
Pharmacology

ISAP

Anti-Infective PK/PD

Integrating Knowledge and Innovating Therapies



Vienna, Austria

21st April 2017

In Collaboration with



**MEDICAL UNIVERSITY
OF VIENNA**



ESCMID

MANAGING INFECTIONS
PROMOTING SCIENCE

Program

- 8.30-9.00 Registration
- 9.00-9.15 **Welcome to the Old General Hospital Vienna**
Markus Zeitlinger
- 9.15-10.15 **Session I: Antimicrobial Resistance** (*Ursula Theuretzbacher, Brian T. Tsuji*)
Preclinical PK/PD: *Jürgen Bulitta*
Translational PK/PD: *Ulrika Simonsson*
Clinical PK/PD: *Jason Roberts*
- 10.15-10.45 Coffee break
- 10:45-12.00 **Session II: Combination Therapy** (*Roger Nation, Hartmut Derendorf*)
Preclinical PK/PD: *Sebastian Wicha*
Translational PK/PD: *Brian Tsuji*
Clinical PK/PD: *Johan Mouton*
- 12.00-12.35 **Pro-Contra I: Clinical Studies vs. Modelling**
Markus Zeitlinger/Lena Friberg
- 12.35-13.25 Lunch
- 13.25-14.40 **Session III: Role of the Immune System** (*Johann Mouton, Lena Friberg*)
Preclinical PK/PD: *Elisabeth Nielson*
Translational PK/PD: *Bernd Jilma*
Clinical PK/PD: *Thomas Walsh*
- 14.40-15.25 **Pro-Contra II: MIC vs. Time-Killing Curves**
Alasdair MacGowan/Hartmut Derendorf
- 15.25-15.45 Coffee break
- 15.45-17.30 **Young Investigators** (Justin Lenhard, Sebastian Wicha)
List of presenting authors is shown below
- 17.30-18.30 **Panel Discussion** (*Ursula Theuretzbacher*)
- 19:30 **Social Event** Dinner at a typical Austrian Heurigen:
10er Marie: Ottakringer Str. 222 – 225, 1160 Wien
<http://www.fuhrgassl-huber.at/10er-marie/>

Conference Chairs

Ursula Theuretzbacher (utheuretzbacher@cefaia.com)
Markus Zeitlinger (markus.zeitlinger@meduniwien.ac.at)

Organizing Committee

Ursula Theuretzbacher	Jian Li	Vincent Tam
Markus Zeitlinger	Alasdair MacGowan	Brian Tsuji
William Couet	Johan Mouton	Paul Tulkens
Lena Friberg	Roger Nation	Francoise Van Bambeke
Hartmut Derendorf	Jason Roberts	Sebastian Wicha

Secretary

Alina Pröll (ISAP_ESCMID@gmx.at)

Registration fee: 130 Euro (early bird until 26.1.2016: 100 Euro). Reduced Fee (Members of ISAP, ESCMID, MUW): 70 Euro (early bird until 26.1.2016: 50 Euro) Students pay 50% of all fees outlined. Fees include lunch and coffee breaks; please note that refunding of registration fee is not possible

Young Investigators Session

Presenting author		Title
Chauzy	Alexia	Pharmacodynamic modeling of checkerboard data obtained with β -lactam/ β -lactamases inhibitor combination: aztreonam-avibactam
Clewe	Oskar	A model-informed pre-clinical pharmacodynamic interaction approach predicts clinical interactions of three antituberculosis drugs
De Cock	Pieter	Population pharmacokinetics of cefazolin before, during and after cardiopulmonary bypass to optimize dosing regimens for children undergoing cardiac surgery
De Laat	Myrthe	Application of Monte Carlo simulation to predict treatment efficacy of three existing antibiotics for the treatment of gonorrhoea under various antimicrobial resistance conditions - a protocol
Deitchmann	Amelia	Exploring the Clinical Pharmacokinetic and Pharmacodynamic Implications of Atypical Nonlinear Plasma Protein Binding
Kristoffersson	Anders	A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic (PKPD) Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β -lactamase-Producing <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Isolates
Heinrichs	Tobias	Lung Tissue Concentrations of Moxifloxacin in Patients with Multidrug Resistant Tuberculosis
Minichmayr	Iris	Comparative pharmacokinetic/pharmacodynamic target attainment of standard vs. intensified dosing for linezolid against <i>S. aureus</i> in plasma and interstitial fluid of sepsis patients
Onufrak	Nikolas	A Novel Mechanism-Based Model to Describe Polymyxin-Based Triple Drug Therapy against KPC-Producing <i>Klebsiella pneumoniae</i>
Rees	Vanessa	Optimised combination therapy: The future to eradicate hypermutable bacteria
Shurko	James	Evaluation of a novel antimicrobial peptide derivative in combination with vancomycin against <i>Staphylococcus aureus</i> ATCC 25923
Siopi	Marisa	A new in vitro biomarker of anidulafungin activity against <i>Aspergillus fumigatus</i> correlates with in vivo outcome
Stainton	Sean	Pharmacokinetics of oral tedizolid in diabetic patients with lower limb infections
Svensson	Robin	Increased bactericidal effect with higher doses of rifampicin for tuberculosis patients revealed using mechanistic pharmacokinetic-pharmacodynamic modelling
Thien	Tran	Host-pathogen-drug interaction transcriptomic studies involving human respiratory epithelial cells, <i>Acinetobacter baumannii</i> , and polymyxin B
Yu	Guozhi	Predicting drug resistance evolution: antimicrobial peptides vs. antibiotics